KalphaTech recently participated in BIO-Europe Spring 2025, held from March 17 to 19 in Milan, one of the largest and most significant global events in the biotechnology and pharmaceutical industries. The conference, attracting over 3700 delegates from over 2000 companies and key industry players, offered unparalleled opportunities for collaboration, innovation, and partnership formation.
At the conference, KalphaTech’s CEO, Stipe Lukin, presented the company’s innovative AI technology platform for solid forms characterization. This platform aims to revolutionize drug development by reducing costs, optimizing resource use, and accelerating time-to-market. It focuses on ultra-high-throughput solid-state screening and property optimization developed on the proprietary technology.
Our team engaged in productive discussions and established valuable connections with CDMOs and CROs. The company showcased its capabilities in solid form landscape exploration and structural characterization, highlighting its potential to address bottlenecks in drug development.
KalphaTech’s innovative approach, driven by proprietary AI models and advanced PXRD analytics, offers rapid, precise, and cost-effective results using minimal sample quantities. This positions KalphaTech as a game-changing solution provider in pharmaceutical R&D.
The event in Milan underscored the importance of early-stage derisking, comprehensive solid form screening, and optimized formulation development. KalphaTech looks forward to building on this momentum at the upcoming BIO-Europe in Vienna this November.
For more information or to discuss potential collaborations, please contact partnerships@kalphatech.com or visit www.kalphatech.com.
